华西口腔医学杂志

• 基础研究 • 上一篇    下一篇

壳聚糖/β-磷酸三钙支架复合骨形态发生蛋白后成骨效能研究

赖仁发 赵清桐 刘湘宁 沈山   

  1. 暨南大学附属第一医院口腔颌面外科, 广东广州510632
  • 收稿日期:2010-10-25 修回日期:2010-10-25 出版日期:2010-10-20 发布日期:2010-10-20
  • 通讯作者: 赖仁发,Tel:13392692190
  • 作者简介:赖仁发(1963—),男,广东人,主任医师,博士
  • 基金资助:

    广东省科技计划基金资助项目(2006B35801004)

Study on osteogenic ability of chitosan/β-tricalcium phosphate scaffold combined with human bone morphogenetic protein

LAI Ren-fa, ZHAO Qing-tong, LIU Xiang-ning, SHEN Shan   

  1. Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital, Jinan University, Guangzhou 510632, China赖仁发,Tel:13392692190
  • Received:2010-10-25 Revised:2010-10-25 Online:2010-10-20 Published:2010-10-20
  • Contact: LAI Ren-fa,Tel:13392692190

摘要:

目的通过壳聚糖(CS)/β-磷酸三钙(TCP)复合重组人骨形态发生蛋白(rhBMP)-2修复兔下颌骨缺损,探索CS/β-TCP作为可注射性人工骨支架材料的可行性。方法24只新西兰大白兔共48侧骨缺损随机分为4组:实验组1植入CS/β-TCP/rhBMP-2、实验组2植入CS/β-TCP、对照组1植入自体骨、对照组2不植入任何材料。于术后2、4、8周分批处死动物,通过苏木精-伊红染色和荧光染料标记组织切片观察新骨形成情况,骨密度仪测量骨密度值。结果术后2、4、8周,不同组间的新生骨面积百分比有显著差异,实验组1明显优于实验组2,并随着观察时间的延长,成骨面积的比例也不断增高。荧光观察示实验组1黄色标记面积较大,红色标记面积较小。实验组1术后各时间点的骨密度值明显优于实验组2和对照组2,而与对照组1间无明显差异。结论CS/β-TCP/rhBMP-2复合体具有良好的生物相容性、降解性、骨引导及骨诱导能力,CS/β-TCP可作为rhBMP-2良好的注射性载体,对于颌骨缺损的修复具有一定的临床价值。

关键词: 骨形态发生蛋白, 壳聚糖/β-磷酸三钙, 组织工程, 支架

Abstract:

Objective Using chitosan(CS)/β-tricalcium phosphate(TCP)/recombinant human bone morphogenetic protein(rhBMP)-2 for the reconstruction of rabbits’mandible defect, to prove the feasibility of CS/β-TCP as an injectable bone tissue engineering scaffold material. Methods Twenty-four New Zealand white rabbits were randomized into 4 groups on average: Experimental group 1 embedding CS/β-TCP/rhBMP-2, experimental group 2 embedding CS/ β-TCP, control group 1 embedding autograft bone group, control group 2 embedding nothing. At 2, 4 and 8 weeks after surgery, all rabbits were executed group by group. The new bone growth situations were observed with hemat oxylin-eosin staining and immunofluorescence microscopy, the bone mineral density was detected by bone sonometers. Results After 2, 4, 8 weeks, there was significant difference among the areas of bone regeneration of all groups. The effect of experimental group 1 was better than experimental group 2. There was significant difference at different times, the areas of bone regeneration was gradually increased with time. The area of stained yellow in experimental group 1 was larger, the area of stained red was smaller. The quantities of bone density in experimental group 1 at every time after surgery were significantly higher than experimental group 1 and control group 2, but had no statistical significance with control group 1. Conclusion CS/β-TCP/rhBMP-2 has good biocompatibility, degradability and the capacity of guided and inducing osteogenesis. CS/β-TCP as a good injection of carrier could become a promising  carrier for rhBMP-2 and potential new degradable biological material for repairing bone defect in clinical application.

Key words: recombinant human bone morphogenetic protein-2, chitosan/β-tricalcium phosphate, tissue engineering, scaffold material